News | Microbion News | Microbion


Microbion Announcements

Apr 25 2024
Microbion Receives Award at Advanced Wound Care Summit USA’s Innovation Showcase
Apr 15 2024
Microbion Selected to Present at Advanced Wound Care Summit USA
Apr 04 2024
Microbion's Topical Pravibismane Phase 1b Moderate or Severe Diabetic Foot Ulcer Infection Study is Published in International Wound Journal
Jan 30 2024
Microbion's Pravibismane Granted Second FDA Orphan Drug Designation for the Treatment of Non-tuberculous Mycobacterial (NTM) Infections
Oct 06 2023
Microbion CEO to Participate in Panel Discussion at BioFuture 2023
Aug 15 2023
Microbion Presented New Pravibismane Data Against Mycobacteroides abscessus at the 6th World Bronchiectasis and NTM Conference
Aug 14 2023
Microbion to Present Design of Ongoing Phase 2 Study Treating Diabetic Foot Ulcer Infections at the 2023 Military Health System Research Symposium
Jun 16 2023
Microbion to Present New Data Demonstrating that Pravibismane Disrupts Bacterial Bioenergetics at ASM Microbe 2023
May 10 2023
Microbion Corp. Presents a Poster on Pravibismane’s Activity Against Diabetic Foot Infection Patient Isolates
Apr 04 2023
Microbion Corp. Granted US Patent for the Use of Inhaled Pravibismane for Pulmonary Infections
Mar 09 2023
Microbion Corporation Initiates Phase 2 Clinical Study Evaluating Topical Pravibismane Treatment of Diabetic Foot Infections
Feb 03 2023
Microbion Corporation CEO to Present at the 2023 BIO CEO & Investor Conference
Nov 03 2022
Microbion Corporation Announces Poster Highlighting Pravibismane Activity Against Common Cystic Fibrosis Pulmonary Pathogens to be Presented at the North American Cystic Fibrosis Conference 2022
Oct 11 2022
Microbion Corporation Announces Data Highlighting Pravibismane’s Effect on Bacterial Energetics Presented at ASM Microbe 2022
Oct 04 2022
Microbion Corporation Announces Granting of a US Patent for a Pharmaceutical Composition of Pravibismane
Jun 07 2022
Microbion Corporation Receives up to $2.1 million in Funding Support from the US Navy in Partnership with CUBRC, Inc. to Advance Topical Pravibismane
Jun 01 2022
Microbion Corporation Announces Data Highlighting In Vitro Activity of Pravibismane in NTM, including Activity Against NTM Causing Intracellular Infections, to be Presented at the Colorado Mycobacteria Conference 2022
Mar 15 2022
Microbion Corporation Announces Granting of a US Patent for the Use of Topical Pravibismane for Diabetic Foot Ulcer Infections
Jul 29 2021
Microbion Corporation Appoints Robert A. Gillam as Chairman of Microbion’s Board of Directors
Feb 22 2021
Microbion Corporation Receives Additional Funding Support from the Cystic Fibrosis Foundation to Speed Advancement of Inhaled Pravibismane
Jan 12 2021
5N Plus Acquires Stake in Microbion and Secures Drug Substance Manufacturing Rights
May 28 2020
Microbion Awarded up to $17.1 Million from CARB-X and the Cystic Fibrosis Foundation to Develop Inhaled Antimicrobial for Chronic Respiratory Infections in CF
May 27 2020
Microbion Corporation Announces Orphan Drug Designation Granted for Pravibismane Suspension for Inhalation by US FDA
May 04 2020
Microbion Corporation Announces Litigation Settlement Agreement, Including a License Agreement, with NYU Langone Health
Oct 28 2019
Microbion Corporation Announces Results from Randomized, Double Blind, Placebo-Controlled Phase 1b Trial of Pravibismane (MBN-101) for Treatment of Moderate to Severe Chronic Infected Diabetic Foot Ulcers
Oct 25 2019
Microbion Corporation Announces Generic Name for Lead Antimicrobial Compound: Pravibismane
Apr 15 2019
Microbion Corporation to Present Data Highlighting Broad Spectrum Activity of BisEDT at the 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)
Jan 04 2017
Quark Venture & GF Securities Invest US$25M in Microbion to Advance New Class of Drugs
Aug 03 2016
MBN-101 Received FDA Fast Track Designation: Adjunctive Treatment of Diabetic Foot Ulcer Infections
Jun 15 2016
Microbion Corporation Announces First Patient Treated in Phase 2a Orthopedic Infection Trial
May 25 2016
MBN-101 Received FDA QIDP Designation for Adjunctive Treatment of Moderate & Severe DFI

Microbion in the News